External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab by Pierre, N, Huynh-Thu, VA, Baiwir, D, Mazzucchelli, G, Fléron, M, Trzpiot, L, Eppe, G, De Pauw, E, Laharie, D, Satsangi, J, Bossuyt, P, Vuitton, L, Vieujean, S, Colombel, J, Meuwis, M, Louis, E, GETAID and the SPARE-Biocycle research group

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM by Yzet, C, Ungaro, R, Bossuyt, P, Baert, F, Vanasek, T, D'Haens, G, Joustra, V, Panaccione, R, Novacek, G, Armuzzi, A, Golovchenko, O, Prymak, O, Goldis, A, Travis, S, Hebuterne, X, Ferrante, M, Rogler, G, Fumery, M, Danese, S, Rydzewska, G, Pariente, B, Hertervig, E, Stanciu, C, Grimaud, J, Diculescu, M, Peyrin-Biroulet, L, Laharie, D, Wright, J, Gomollon, F, Gubonina, I, Schreiber, S, Motoya, S, Hellstrom, P, Halfvarson, J, Colombel, J